Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model

Sponsored by:

Date:

May 13, 2025

Time (PT):

11:00 AM

Duration (min):

In this exclusive session, Stephanie Piekos, PhD, Senior Scientist at Boehringer Ingelheim, shares insights into the challenges of evaluating AO substrates and how more predictive, human-relevant models are shaping the future of DMPK studies.

Understanding aldehyde oxidase (AO)-mediated metabolism has become increasingly critical in drug development, as traditional models often fail to capture this non-CYP clearance pathway with sufficient accuracy. Join us to explore how TruVivo‚ÄîLifeNet Health's all-human 2D+ hepatic system‚Äîdelivers enhanced AO activity compared to conventional in vitro models. With improved enzyme stability and metabolic function over extended culture periods, TruVivo offers a powerful platform for identifying metabolic liabilities, predicting human clearance, and bridging translational gaps in early development. This session is a must for scientists focused on advancing preclinical models for more accurate and reliable decision-making.

Presenters

Stephanie Piekos

Boehringer Ingelheim (Nonclinical Drug Metabolism and Pharmacokinetics Group)

Principal Scientist

Stephanie is currently a Principal Scientist in the Nonclinical Drug Metabolism and Pharmacokinetics group at Boehringer Ingelheim in Ridgefield, Connecticut.

LifeNet Health LifeSciences

LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeNet Health LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services.

Content Partners

Scientist.com

Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.

We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.

Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

‍

Topics

Pharmacology

Cell Culture & Characterization

DMPK

Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model

Presenters

Stephanie Piekos

Sponsor

LifeNet Health LifeSciences

Content Partners

Scientist.com

Topics

Watch Now

Related Content

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Screening the Unscreenable: Expanding the Reach of Drug Discovery

Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control

Precision in Human Biological Samples: Leveraging Regulatory Rigor and Deep Data for Advanced Disease Research

Detecting Early Synaptic Failure in Prion Disease Using Organoid Models

Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping

Bridging Mouse Models and Human Inflammatory Bowel Disease: in vivo Pharmacology, Histology and Biomarkers

Screening the Unscreenable: Expanding the Reach of Drug Discovery

High-Throughput-qPCR and Transcriptomics: Powering the Next Generation of Drug Discovery

From Clinical Data to Actionable Assets for Pharmaceutical R&D

Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults

Patient Data: Opportunities for Rare Diseases, Cell and Gene Therapies, and Oncology

Trials and tribulations of drug development

Webinar Series: Early patient preferences for patient-focused drug development

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Cutting Edge Conversations: Discovering New Innovations in Oncology

Translational Success in Inflammasome Drug Discovery: How Advanced Models and Integrated Assays Can Reduce Attrition

How to Avoid Expensive Redesign Cycles in Antibody Discovery

Recent Advances in Crystalline Polymorphism Research in Drug Development

Improving Confidence in Thyroid Hormone Disruption Assessment Using a Novel Human-Relevant In Vitro Model

Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform

Beyond Exposure: Integrating PK/PD for Translational Predictive Power

Fulfilling the Gap: Innovative Critical Reagents for Non-Human Primate Preclinical Studies

Advancing ADC Development: Leveraging AI and Translational Preclinical Models to Improve Clinical Predictability

Scaling AAV9 Manufacturing: A Blueprint for Clinical-Grade Gene Therapy Production

Human iPSC-Derived Sensory Neurons for Functional Sensory Biology and Pharmacology Research

From Biopsy to Better Decisions: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Accelerating Conjugation Process Development for Next-Generation ADCs: Key Considerations and Platform Strategies

Epigenomics at 360 in Liquid Biopsy: Approaches and Case Studies for Biomarker Discovery and Drug Development

The Sound of Science: Mapping the Tumor Microenvironment for Advanced Therapeutic Strategies

Next-Generation TCR-Like Antibodies With Improved Specificity Profiles

ADC Payload-Linker CMC Process Development Strategy

De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms

Photoreceptor Cell Therapy to Treat Advanced Retinal Degeneration

Clinical Applications of Optical Cerebral Blood Flow Imaging

ADCs on The Horizon: The Performance and Prospect of Cell Line Development Platform ‚Äî AmigoCHO

Selectivity Profiling: Unbiased Analysis of Compound Selectivity in Drug Discovery

Building New Approach Methodologies for Angiogenesis and Vascularized Models

Using ALS Patient-Derived Motor Neurons to Study TDP-43 Mislocalization

Vevo Ask The Experts: Oncology Imaging

hiPSC-Cardiomyocyte Platforms Enabling Comprehensive Cardiac Toxicity and Drug Efficacy Evaluation

Protein-Protein Interaction (PPI) Landscape - Sequence-to-Affinity Heatmaps for High-Throughput Antibody Optimization

Human Biological Samples in Research: Quality, Compliance, and Clinical Relevance

Combination Therapy for Glioblastoma: A Personalized, AI-Driven Approach

In Vivo panCAR Therapy Using Circular RNA for the Treatment of Autoimmune Disease

From Single Domain to Single B: Leveraging Biointron's Expertise for Antibody Discovery Success

Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies

Non CYP Mediated Metabolism Pathways and In Vitro Evaluation Strategies

Uniting biology and digital drug discovery to identify new therapeutic opportunities in neurodegeneration

Enhance Your Tissue Processing Efficiency with the STEMprep Tissue Dissociator

Reprogramming Mouse Fibroblasts Into Induced Cardiomyocytes: Age-Related, Metabolic, and Epigenetic Barriers

Novel Applications of the Cellular Thermal Shift Assay (CETSA) Provide New Insights for Drug Discovery

Vaccine-Boosting CAR T Cells Against Solid Tumors

Exploring the iPSC-Derived Neuronal-Glia Co-culture System: A Powerful Drug Discovery Platform for Studying Neurodegenerative Diseases

Integrating Regulatory Guidance and Sustainable Skin Procurement for Consistent Execution of In Vitro Permeation Testing

Launch Event: Propelling Boundaries - Innovative Technologies in Early Drug Discovery

Advances in Preclinical Research using Human Co-culture Models: Applications in Immunology, Infectious Disease, and Oncology

Cell-Based Assays for Immuno-oncology

Artificial Intelligence in Preclinical Research: Pathology, Biospecimens, and Model Selection

CAR Finder - A Platform for Rapid CAR T Cell Screening

CRISPR Gene Editing in Primary T Cells: A Case Study in the Fight Against HIV

Improved Clearance Predictions for Aldehyde Oxidase Substrates Using TruVivo, a Novel Human Hepatocyte Model

Introduction to Bispecific Antibodies and Their Production

The Hidden Variable in Your Intestinal Organoids: Enhancing Differentiation for a More Predictive Model

Integrating Functionalized Multi-omics in Oncology Drug Discovery

Fresh or Cryopreserved Leukopaks? Assessing the Impact of Different Storage Conditions on Leukopak Stability

Breaking the Bottleneck: Harnessing Proteomics Services to Overcome Challenges in Clinical Research

Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI

Biomarkers from Bench to Bedside: Tools, Targets, and Translational Insights